Clinical trial NCT03216200: Early Feasibility Study to Evaluate the Efficacy of the RenewalNail™ Plasma Treatment System in Patients With Onychomycosis (Fungal Nail)
Official title: A Single Center Open Label Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail) of the Hallux Caused by Trichophyton Rubrum or Trichophyton Mentagrophytes.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Onychomycosis of Toenail
Onychomycosis
Lead sponsor: DeviceFarm, Inc.
Sponsor class: INDUSTRY
First posted: 2017-07-13
Enrollment: 5
Sex: ALL
Minimum age (years): 21
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: single center open-label study
Primary purpose: TREATMENT

Brief summary: A study to determine if a three-treatment protocol with the RenewalNail™ plasma treatment system over a week will result in mycological cure and/or clear nail growth on the treated hallux toe.

Detailed description: The purpose of this study is to assess the clinical feasibility of DeviceFarm, Inc.'s RenewalNail™ system and the treatment protocol that was developed based on extensive laboratory testing on human cadaver nails. The Protocol calls for three 45-minute treatments performed over a week to achieve mycological cure. Mycological cure will be assessed with two consecutive mycological culture tests done over a week following the third treatment. Two consecutive negative mycology culture results confirm the elimination of fungus causing onychomycosis infection, as recommended by recent FDA guidance. There will be no placebo arm in the study. Clear nail growth will be documented and assessed by photography for 5 months after treatment.

Eligibility criteria: Inclusion Criteria:

* Subjects who are between 21 to 75 years (inclusive) of age;
* Subjects who are in good general health and free from any clinically significant disease that might interfere with the study evaluations;
* Subjects with established clinical diagnosis of distal subungual onychomycosis;
* Subjects with at least one big toe nail involved with 20-75% infection;
* Subjects with both positive KOH and culture for onychomycosis dermatophytes in screening of nail samples;
* Subjects whose infection is confirmed to be caused by T. rubrum or T. mentagrophytes;
* Subjects who are willing and able to refrain from employing other (non-study) treatments (traditional or alternative) for his or her toenail onychomycosis throughout study participation;
* Subjects who are willing and able to refrain from the use of nail cosmetics such as clear and/or colored nail lacquers during the week of treatment (from Study Visits 1 through 3);
* Subjects who are willing and able to give written informed consent and able to adhere to procedures and visit schedules;
* Women of childbearing potential who are currently sexually active must agree to use a medically accepted method of contraception while receiving protocol specified treatment. Methods include condoms (male or female), diaphragm or cervical cap with spermicide, medically prescribed intrauterine device, oral or systemic hormonal contraceptive, surgical sterilization (e.g., hysterectomy or tubal ligation);
* Women of childbearing potential who are not currently sexually active must agree to use a medically accepted method of contraception should they become sexually active while participating in the study;
* Women of childbearing potential must have a negative pregnancy test prior to start of study.

Exclusion Criteria:

* Subjects with onychomycosis infection involving lunula of the affected toenail(s) or spikes of disease extending to nail matrix in the affected big toenail;
* Subjects whose foot is too large (larger than US men's size 13) or too small (smaller than US women's size 3) to properly fit into the plasma treatment device;
* Subjects whose affected big toenail cannot become normal in the opinion of the investigator;
* Subjects who received topical antifungal treatment of the nails within 2 weeks before study initiation;
* Subjects who received systemic antifungal treatment within 3 months before study initiation;
* Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding treatment;
* Subjects who are immunocompromised (e.g. adrenal insufficiency, diabetes mellitus, febrile neutropenia, and the human immunodeficiency virus infected);
* Subjects with any pacemakers, or any metallic implants or prostheses in the vicinity of the treatment site (such as ankle, foot, etc.);
* Subjects with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with study evaluations or optimal participation in the study;
* Subjects who feel they cannot sit for 45 minutes at a time during the treatment;
* Subjects who are part of the staff personnel directly involved with this study or who are family members of the investigational study staff;
* Subjects with known allergy to any of the tested treatment products \[i.e. perfluorocarbons and plastic polycarbonate\];
* Women who are pregnant, breastfeeding, or planning pregnancy prior to the end of study participation;

Primary outcomes:
measure: Mycological Cure
timeFrame: 2 cultures taken a week apart within 2 weeks after the first treatment
Secondary outcomes:
measure: Clear Nail Growth
timeFrame: 5 months after the first treatment
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: David L. Kahan, DPM
state: California
Study officials:
affiliation: DeviceFarm, Inc.
name: Jeffrey N Roe, PhD
role: PRINCIPAL_INVESTIGATOR
References: